Patents by Inventor Frank Navas, III
Frank Navas, III has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210206715Abstract: Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R1, R2, R3, R4, R5, R6, R7, R11, R12, R13, R14, R15, R16, R17, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.Type: ApplicationFiled: March 19, 2021Publication date: July 8, 2021Applicants: Duke University, The University of North Carolina at Chapel HillInventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas, Ramesh Gopalaswamy, Xiaofei Liang, Frank Navas, III
-
Patent number: 11034649Abstract: Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R1, R2, R3, R4, R5, R6, R7, R11, R12, R13, R14, R15, R16, R17, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.Type: GrantFiled: April 25, 2017Date of Patent: June 15, 2021Assignees: DUKE UNIVERSITY, THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILLInventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas, Ramesh Gopalaswamy, Xiaofei Liang, Frank Navas, III
-
Patent number: 10550074Abstract: Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R1, R2, R3, R4, R5, R6, R7, R11, R12, R13, R14, R15, R16, R17, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.Type: GrantFiled: February 7, 2019Date of Patent: February 4, 2020Assignees: DUKE UNIVERSITY, THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILLInventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas, Ramesh Gopalaswamy, Xiaofei Liang, Frank Navas, III
-
Publication number: 20190367446Abstract: Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R1, R2, R3, R4, R5, R6, R7, R11, R12, R13, R14, R15, R16, R17, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.Type: ApplicationFiled: April 25, 2017Publication date: December 5, 2019Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas, Ramesh Gopalaswamy, Xiaofei Liang, Frank Navas, III
-
Publication number: 20190169114Abstract: Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R1, R2, R3, R4, R5, R6, R7, R11, R12, R13, R14, R15, R16, R17, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.Type: ApplicationFiled: February 7, 2019Publication date: June 6, 2019Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas, Ramesh Gopalaswamy, Xiaofei Liang, Frank Navas, III
-
Patent number: 8158665Abstract: The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.Type: GrantFiled: March 9, 2010Date of Patent: April 17, 2012Assignee: GlaxoSmithKline LLCInventors: Richard Caldwell, David Norman Deaton, Robert Blount McFadyen, Frank Navas, III, Paul Kenneth Spearing
-
Patent number: 7960552Abstract: The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.Type: GrantFiled: October 23, 2007Date of Patent: June 14, 2011Assignee: GlaxoSmithKline LLCInventors: Jonathan York Bass, III, Justin Caravella, David Norman Deaton, Robert Blount McFadyen, Frank Navas, III, Paul Kenneth Spearing
-
Publication number: 20110034507Abstract: The present invention relates to farnesoid X receptors (FXR, NR1H4). FXR is a member of the nuclear receptor class of ligand-activate transcription factors. More particularly, the present invention relates to compounds useful as agonists for FXR, pharmaceutical formulations comprising such compounds, and therapeutic use of the same. Novel isoxazole compounds are disclosed as part of pharmaceutical compositions for the treatment of a condition mediated by decreased FXR activity, such as obesity, diabetes, cholestatic liver disease, liver fibrosis, and metabolic syndrome.Type: ApplicationFiled: June 13, 2008Publication date: February 10, 2011Applicant: SMITHKLINE BEECHAM CORPORATIONInventors: Adwoa Akwabi-Ameyaw, David Norman Deaton, Robert Blount McFadyen, Frank Navas, III
-
Publication number: 20100249179Abstract: The present invention provides novel isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.Type: ApplicationFiled: June 13, 2008Publication date: September 30, 2010Applicant: SMITHKLINE BEECHAM CORPORATIONInventors: David Norman Deaton, Frank Navas, III, Paul Kenneth Spearing
-
Patent number: 7799828Abstract: The present invention relates to novel compounds with a variety of therapeutic uses, more particularly novel substituted cyclic alkylidene compounds that are particularly useful for selective estrogen receptor modulation.Type: GrantFiled: June 8, 2009Date of Patent: September 21, 2010Assignee: GlaxoSmithKline LLCInventors: Jing Fang, Dennis Heyer, Aaron Bayne Miller, Frank Navas, III, Terrence Lee Smalley, Jr., William J. Zuercher, Subba Reddy Katamreddy
-
Publication number: 20100160398Abstract: The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.Type: ApplicationFiled: March 9, 2010Publication date: June 24, 2010Inventors: Richard Caldwell, David Norman Deaton, Robert Blount McFadyen, Frank Navas, III, Paul Kenneth Spearing
-
Publication number: 20100120775Abstract: The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.Type: ApplicationFiled: October 23, 2007Publication date: May 13, 2010Applicant: SMITHKLINE BEECHAM CORPORATIONInventors: Jonathan York Bass, III, David Norman Deaton, Justin Caravella, Robert Blount McFadyen, Frank Navas, III, Paul Kenneth Spearing
-
Patent number: 7705028Abstract: The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.Type: GrantFiled: December 13, 2006Date of Patent: April 27, 2010Assignee: GlaxoSmithKline LLCInventors: Richard Caldwell, David Norman Deaton, Robert Blout McFayden, Frank Navas, III, Paul Kenneth Spearing
-
Patent number: 7649093Abstract: The present invention relates to cycloalkylidene compounds with a variety of therapeutic uses, more particularly novel naphthalene compounds that are particularly useful for selective estrogen receptor modulation.Type: GrantFiled: June 21, 2005Date of Patent: January 19, 2010Assignee: Glaxo Smith Kline LLCInventors: Dennis Heyer, Jing Fang, Frank Navas, III, Subba Reddy Katamreddy, Jennifer Poole Peckham, Philip Stewart Turnbull, Aaron Bayne Miller, Adwoa Akwabi-Ameyaw
-
Publication number: 20090253659Abstract: The present invention relates to novel compounds with a variety of therapeutic uses, more particularly novel substituted cyclic alkylidene compounds that are particularly useful for selective estrogen receptor modulation.Type: ApplicationFiled: June 8, 2009Publication date: October 8, 2009Inventors: Jing Fang, Dennis Heyer, Aaron Bayne Miller, Frank Navas, III, Terrence Lee Smalley, JR., William J. Zuercher, Subba Reddy Katamreddy
-
Patent number: 7569601Abstract: The present invention relates to novel compounds with a variety of therapeutic uses, more particularly novel substituted cyclic alkylidene compounds that are particularly useful for selective estrogen receptor modulation.Type: GrantFiled: May 14, 2007Date of Patent: August 4, 2009Assignee: SmithKline Beecham CorporationInventors: Jing Fang, Dennis Heyer, Aaron Bayne Miller, Frank Navas, III, Terrence Lee Smalley, Jr., William J. Zuercher, Subba Reddy Katamreddy
-
Patent number: 7560589Abstract: The present invention relates to novel compounds with a variety of therapeutic uses, more particularly novel substituted cyclic alkylidene compounds that are particularly useful for selective estrogen receptor modulation.Type: GrantFiled: July 27, 2004Date of Patent: July 14, 2009Assignee: SmithKline Beecham CorporationInventors: Jonathan E. Britton, Jing Fang, Dennis Heyer, Aaron Bayne Miller, Frank Navas, III, Terrence Lee Smalley, Jr., William J. Zuercher, Subba Reddy Katamreddy
-
Publication number: 20070276000Abstract: The present invention relates to cycloalkylidene compounds with a variety of therapeutic uses, more particularly novel naphthalene compounds that are particularly useful for selective estrogen modulation.Type: ApplicationFiled: June 21, 2005Publication date: November 29, 2007Inventors: Dennis Heyer, Jing Fang, Frank Navas III, Subba Katamreddy, Jennifer Peckham, Philip Turnbull, Aaron Miller, Adwoa Akwabi-Ameyan, Charles Dadswell
-
Publication number: 20070123548Abstract: This invention relates to compounds of formula (I) or (II) wherein, in either formula, independently; R1 and R2 are the same or are different and are C1-8 alkyl, C2-8 alkylene, C3-8 cycloalkyl, aryl, heteroaryl, heterocycloalkyl, C3-6 cycloalkylaryl, or heterocycloaryl; wherein said alkyl, alkylene, cycloalkyl, aryl, heteroaryl, heterocyclyl, cycloalkylaryl, or heterocycloaryl are unsubstituted or substituted by one or more groups selected from the group consisting of halogen, C1-8 alkyl, C1-8alkoxy, C1-8thioalkoxy, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, CF3, SCF3, NHC(O)nR5, S(O)mR5, S(O)2NR5R6, C(S)NR5R6, CONR5R6, C(O)nR5; n is 0, 1 or 2; m is 0, 1 or 2; R5 is hydrogen, alkyl, aryl, alkylaryl, heterocycloalkyl, or heteroaryl and is unsubstituted or substituted by one or more groups selected from the group consisting of alkyl, C1-8alkoxy, aryl, heteroaryl, halogen, NO2, CN, N3, SCF3, and CF3; R6 is hydrogen, alkyl, aryl, alkylaryl, heterocycloalkyl, or heteroaryl and is unsubstituted or subType: ApplicationFiled: February 3, 2005Publication date: May 31, 2007Inventors: David Cowan, Frank Navas III, Jeffrey Oplinger
-
Patent number: 6884801Abstract: Compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof are disclosed. Such compounds are useful in the treatment of Alpha-1A mediated diseases or conditions such as urinary incontinence.Type: GrantFiled: April 28, 2000Date of Patent: April 26, 2005Assignee: SmithKline Beecham CorporationInventors: Eric Cleveland Bigham, Michael Joseph Bishop, David Harold Drewry, Deanna Trojan Garrison, Stephen Joseph Hodson, Frank Navas, III, Jason D. Speake